Changchang Lu

621 total citations
20 papers, 448 citations indexed

About

Changchang Lu is a scholar working on Oncology, Immunology and Epidemiology. According to data from OpenAlex, Changchang Lu has authored 20 papers receiving a total of 448 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 11 papers in Immunology and 4 papers in Epidemiology. Recurrent topics in Changchang Lu's work include Pancreatic and Hepatic Oncology Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (6 papers). Changchang Lu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (8 papers), Cancer Immunotherapy and Biomarkers (7 papers) and Immunotherapy and Immune Responses (6 papers). Changchang Lu collaborates with scholars based in China and India. Changchang Lu's co-authors include Liyun Xu, Yanyan Huang, Dongdong Chen, Xiaoguang Liu, Jian-Ying He, Yongkui Zhang, Guoqing Wu, Wei Yu, Hanbo Le and Xuetian Yue and has published in prestigious journals such as SHILAP Revista de lepidopterología, Biomaterials and Frontiers in Immunology.

In The Last Decade

Changchang Lu

19 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Changchang Lu China	9	260	247	131	74	58	20	448
Naoshi Kawamura Japan	10	233 0.9×	204 0.8×	156 1.2×	57 0.8×	46 0.8×	12	456
Wenchao Wu China	8	197 0.8×	273 1.1×	178 1.4×	122 1.6×	35 0.6×	14	488
Shalom Lerrer United States	9	278 1.1×	226 0.9×	202 1.5×	122 1.6×	51 0.9×	17	507
Katrin Rabold Netherlands	9	229 0.9×	287 1.2×	203 1.5×	110 1.5×	46 0.8×	14	511
Ravindra Uppaluri United States	10	313 1.2×	390 1.6×	159 1.2×	62 0.8×	44 0.8×	25	590
Jessica D. Weaver United States	6	302 1.2×	377 1.5×	106 0.8×	81 1.1×	32 0.6×	9	514
Kezhuo Yu China	3	278 1.1×	306 1.2×	240 1.8×	108 1.5×	80 1.4×	3	547
Fabio Scirocchi Italy	10	193 0.7×	155 0.6×	130 1.0×	87 1.2×	83 1.4×	15	395
Qinglin Fei China	8	210 0.8×	185 0.7×	134 1.0×	52 0.7×	40 0.7×	16	362
Christopher McQuinn United States	3	337 1.3×	187 0.8×	106 0.8×	62 0.8×	33 0.6×	6	439

Countries citing papers authored by Changchang Lu

Since Specialization

Citations

This map shows the geographic impact of Changchang Lu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Changchang Lu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Changchang Lu more than expected).

Fields of papers citing papers by Changchang Lu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Changchang Lu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Changchang Lu. The network helps show where Changchang Lu may publish in the future.

Co-authorship network of co-authors of Changchang Lu

This figure shows the co-authorship network connecting the top 25 collaborators of Changchang Lu. A scholar is included among the top collaborators of Changchang Lu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Changchang Lu. Changchang Lu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sun, Mengna, Tianyu Shi, Mengru Li, et al.. (2024). An Immunomodulator‐Boosted Lactococcus Lactis Platform For Enhanced In Situ Tumor Vaccine. Advanced Healthcare Materials. 13(28). e2401635–e2401635. 3 indexed citations

Qiu, Xin, Changchang Lu, Huizi Sha, et al.. (2024). Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial. Frontiers in Immunology. 15. 1210859–1210859. 4 indexed citations

Lu, Changchang, et al.. (2024). Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V. SHILAP Revista de lepidopterología. 24(5). 1424–1434. 1 indexed citations

Shi, Tianyu, Mengna Sun, Mengru Li, et al.. (2024). Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors. Biomaterials. 309. 122607–122607. 3 indexed citations

Ming, Xinliang, Ze Yang, Zhiguo Wang, et al.. (2024). A chimeric peptide promotes immune surveillance of senescent cells in injury, fibrosis, tumorigenesis and aging. Nature Aging. 5(1). 28–47. 16 indexed citations

Shi, Tianyu, Mengna Sun, Changchang Lu, & Fanyan Meng. (2023). Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines. Frontiers in Immunology. 14. 1125253–1125253. 8 indexed citations

Qiu, Xin, Zhan Shi, Fan Tong, et al.. (2023). Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Human Vaccines & Immunotherapeutics. 19(1). 2178791–2178791. 16 indexed citations

Shao, Jie, Qin Liu, Jie Shen, et al.. (2022). Advanced Pancreatic Cancer Patient Benefit From Personalized Neoantigen Nanovaccine Based Immunotherapy: A Case Report. Frontiers in Immunology. 13. 799026–799026. 9 indexed citations

Shi, Zhan, Ju Yang, Weiwei Kong, et al.. (2022). Use of Nab-Paclitaxel Plus Gemcitabine Followed by Hypofractionated Tomotherapy With Simultaneous Integrated Boost in Patients With Locally Advanced Pancreatic Cancer. Frontiers in Oncology. 12. 782730–782730. 3 indexed citations

10.

Lu, Changchang, Hao Cheng, Weiwei Kong, et al.. (2022). Case Report: Pathologic Complete Response to Induction Therapy in a Patient With Potentially Resectable Pancreatic Cancer. Frontiers in Oncology. 12. 898119–898119.

11.

Du, Juan, Xin Qiu, Changchang Lu, et al.. (2022). Molecular Landscape and Prognostic Biomarker Analysis of Advanced Pancreatic Cancer and Predictors of Treatment Efficacy of AG Chemotherapy. Frontiers in Oncology. 12. 844527–844527. 4 indexed citations

12.

Lu, Changchang, Weiwei Kong, Ju Dong Yang, et al.. (2022). Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer. Frontiers in Oncology. 12. 879661–879661. 2 indexed citations

13.

Zhang, Qianning, Xin Qiu, Changchang Lu, et al.. (2022). Efficacy and safety of immune checkpoint inhibitors in advanced pancreatic cancer: A real world study in Chinese cohort. Human Vaccines & Immunotherapeutics. 18(6). 2143154–2143154. 5 indexed citations

14.

Qiu, Xin, Changchang Lu, Zhengyun Zou, et al.. (2021). AGIG Chemo-Immunotherapy in Patients With Advanced Pancreatic Cancer: A Single-Arm, Single-Center, Phase 2 Study. Frontiers in Oncology. 11. 693386–693386. 2 indexed citations

15.

Liu, Wen, Fuxiang Bai, Lu Ding, et al.. (2020). IL‐6 promotes metastasis of non‐small‐cell lung cancer by up‐regulating TIM‐4 via NF‐κB. Cell Proliferation. 53(3). e12776–e12776. 106 indexed citations

16.

Xu, Liyun, Changchang Lu, Yanyan Huang, et al.. (2018). SPINK1 promotes cell growth and metastasis of lung adenocarcinoma and acts as a novel prognostic biomarker. BMB Reports. 51(12). 648–653. 55 indexed citations

17.

Xu, Liyun, Yanyan Huang, Wei Yu, et al.. (2015). Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma. International Immunopharmacology. 29(2). 635–641. 172 indexed citations

18.

Xu, Liyun, Dongdong Chen, Changchang Lu, et al.. (2015). Advanced Lung Cancer Is Associated with Decreased Expression of Perforin, CD95, CD38 by Circulating CD3+CD8+ T Lymphocytes.. PubMed. 45(5). 528–32. 9 indexed citations

19.

Chen, Dongdong, Jian-Ying He, Changchang Lu, et al.. (2014). Increased Expression of T Cell Immunoglobulin and Mucin Domain 4 Is Positively Associated with the Disease Severity of Patients with Ankylosing Spondylitis. Inflammation. 38(3). 935–940. 11 indexed citations

20.

Xu, Liyun, Dongdong Chen, Jian-Ying He, et al.. (2014). Tim-3 Expression by Peripheral Natural Killer Cells and Natural Killer T Cells Increases in Patients with Lung Cancer - Reduction after Surgical Resection. Asian Pacific Journal of Cancer Prevention. 15(22). 9945–9948. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact